In severe treatment-resistant depression, long-term data show VNS benefits not only persist for 2 years but also continue to emerge in late responders.

Nyxoah SA (NYXH) 44th Annual J.P. Morgan Healthcare Conference January 15, 2026 3:00 PM ESTCompany ParticipantsOlivier Taelman - CEO & ...

Find out how vagus nerve stimulation delivers durable symptom relief and quality of life gains in treatment resistant depression patients.

A larger trial of trigeminal nerve stimulation in children with ADHD produce results that differ from an earlier pilot study, raising new questions about its efficacy.

While proven a safe method, external trigeminal nerve stimulation was nonsuperior to sham treatment as early as 4 weeks and as long as 6 months in children and adolescents with ADHD, according to data ...

The first-of-a-kind brain-stimulation device approved to treat attention-deficit/hyperactivity disorder (ADHD) in the US has ...

By Tarun Sai Lomte Two-year data show that adding VNS to standard care can produce lasting symptom, function, and ...

Craniofacial pain is among the most common chronic pain conditions, affecting more than one-fifth of the U.S. population 1. With this milestone, Curonix advances its mission to drive full-body PNS ...

Among patients with treatment-resistant major depressive disorder (MDD), most of those who achieve benefit with 12 m ...

A large multicenter clinical trial led by King's College London with 150 children and adolescents has shown that a device cleared by the US FDA to treat ADHD is not effective in reducing symptoms. The ...